Trogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastoma
Trogenix has dosed the first patient in its Phase I/II ADePT clinical trial of TGX-007, a dual-payload AAV-based gene therapy for newly diagnosed and recurrent glioblastoma, an aggressive form of brain […]





